Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):696–700. doi: 10.1128/aac.40.3.696

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.

J K James 1, S M Palmer 1, D P Levine 1, M J Rybak 1
PMCID: PMC163182  PMID: 8851595

Abstract

Ten patients were treated with conventional dosing (CD) and continuous-infusion (CI) vancomycin therapy in this prospective, randomized, crossover study. Patients were randomized to receive either CD or CI therapy for 2 consecutive days and then crossed over to receive the opposite regimen for 2 days. CD therapy consisted of 1 g of vancomycin every 12 h. CI therapy consisted of a 500-mg loading dose followed by 2 g infused over 24 h. Ten serum samples were obtained on the second day of each therapy for pharmacokinetic and pharmacodynamic analyses. Two clinical isolates of Staphylococcus aureus, one methicillin sensitive (MSSA 1199) and one methicillin resistant (MRSA 494), were chosen for pharmacodynamic evaluation of both regimens. The patient demographics (means +/- standard deviations [SD]) were as follows: sex, six males, four females; age, 36 +/- 11 years; and serum creatinine, 0.72 +/- 0.18 mg/dl. Mean pharmacokinetic parameters +/- SD for CD therapy were as follows: elimination rate constant, 0.16 +/- 0.07 h-1; half-life, 5.6 +/- 3.5 h; volume of distribution, 33.7 +/- 25 liters, 0.5 +/- 0.2 liters/kg; maximum concentration in serum, 53.4 +/- 19.3 micrograms/ml; and minimum concentration, 8.4 +/- 5.9 micrograms/ml. The steady-state concentration for CI was 20.2 +/- 11.1 micrograms/ml. Overall, both regimens resulted in the MIC being exceeded 100% of the time. The mean CD trough serum bactericidal titer (SBT) was 1:8, and the average CI SBTs were 1:16 for both isolates. Even though there was no statistically significant difference between CD trough and CI SBTs, the CI SBTs remained > 1:8 for 100% of the time versus 60% of the time for CD therapy. During CI therapy, 20 and 40% of the patients maintained SBTs of > 1:32 throughout the dosing interval for MSSA 1199 and MRSA 494, respectively. During CD therapy, however, only 10% of patients maintained SBTs of > 1:32 during the entire dosing interval for both isolates. The mean areas under the bactericidal titer-time curve (AUBC24s) +/- SD for MSSA 1199 were 528 +/- 263 for CD therapy and 547 +/- 390 for CI therapy. The mean AUBC24s +/- SD against MRSA 494 were 531 +/- 247 for CD and 548 +/- 293 for CI therapy. Similar to the AUBC24, the mean area under the concentration-time curve for a 24-h dosing interval divided by the MIC (AUC/MIC24) ratios +/- SD were 550.0 +/- 265.7 for CD and 552.6 +/- 373.4 for CI therapy, respectively. No statistically significant differences were found between any of the pharmacodynamic parameters for CD and CI therapy. In addition, no adverse effects with either CD or CI therapy were observed during the study. We conclude that CI and CD vancomycin therapy demonstrated equivalent pharmacodynamic activities. Although CI therapy was more likely to result in SBTs that remained above 1:8 for the entire regimen, the clinical impact of this result is unknown. Serum drug concentration variability was observed with both treatment regimens but to a lesser extent with CI administration. CI administration of vancomycin should be further evaluated to determine the clinical utility of this method of administration.

Full Text

The Full Text of this article is available as a PDF (206.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman B. H., Vannier A. M., Eudy E. B. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother. 1992 Aug;36(8):1766–1769. doi: 10.1128/aac.36.8.1766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barois A., Estournet B., Moranne J. B., Piliot J., Chabenat C., Bataille J. Infections ventriculaires à staphylocoque. Traitement par la vancomycine en perfusion veineuse continue. Presse Med. 1986 Oct 18;15(36):1805–1808. [PubMed] [Google Scholar]
  3. Barriere S. L., Ely E., Kapusnik J. E., Gambertoglio J. G. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985 Jul;16(1):49–59. doi: 10.1093/jac/16.1.49. [DOI] [PubMed] [Google Scholar]
  4. Brinquin L., Rousseau J. M., Boulesteix G., Diraison Y., Bonsignour J. P. Vancomycine en perfusion continue dans les méningites à staphylocoques post-neurochirurgicales de l'adulte. Presse Med. 1993 Nov 20;22(36):1815–1817. [PubMed] [Google Scholar]
  5. Bush K. Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'. Antimicrob Agents Chemother. 1989 Mar;33(3):264–270. doi: 10.1128/aac.33.3.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cantú T. G., Yamanaka-Yuen N. A., Lietman P. S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994 Apr;18(4):533–543. [PubMed] [Google Scholar]
  7. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  8. Craig W. A., Ebert S. C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992 Dec;36(12):2577–2583. doi: 10.1128/aac.36.12.2577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edwards D. J., Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm. 1987 Aug;6(8):652–654. [PubMed] [Google Scholar]
  10. Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Freeman C. D., Quintiliani R., Nightingale C. H. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 1993 May;27(5):594–598. doi: 10.1177/106002809302700514. [DOI] [PubMed] [Google Scholar]
  12. LOURIA D. B., KAMINSKI T., BUCHMAN J. Vancomycin in severe staphylococcal infections. Arch Intern Med. 1961 Feb;107:225–240. doi: 10.1001/archinte.1961.03620020075007. [DOI] [PubMed] [Google Scholar]
  13. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  14. Moellering R. C., Jr Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis. 1994 Apr;18(4):544–546. doi: 10.1093/clinids/18.4.544. [DOI] [PubMed] [Google Scholar]
  15. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  16. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  17. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Oster S. E., Chirurgi V. A., Goldberg A. A., Aiken S., McCabe R. E. Ampicillin-resistant enterococcal species in an acute-care hospital. Antimicrob Agents Chemother. 1990 Sep;34(9):1821–1823. doi: 10.1128/aac.34.9.1821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Polk R. E., Healy D. P., Schwartz L. B., Rock D. T., Garson M. L., Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis. 1988 Mar;157(3):502–507. doi: 10.1093/infdis/157.3.502. [DOI] [PubMed] [Google Scholar]
  20. Pryka R. D. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother. 1994 Dec;28(12):1397–1399. doi: 10.1177/106002809402801212. [DOI] [PubMed] [Google Scholar]
  21. Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
  22. Rybak M. J., Albrecht L. M., Berman J. R., Warbasse L. H., Svensson C. K. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother. 1990 May;34(5):792–795. doi: 10.1128/aac.34.5.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rybak M. J., Bailey E. M., Lamp K. C., Kaatz G. W. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother. 1992 May;36(5):1109–1114. doi: 10.1128/aac.36.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schaad U. B., McCracken G. H., Jr, Nelson J. D. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr. 1980 Jan;96(1):119–126. doi: 10.1016/s0022-3476(80)80347-7. [DOI] [PubMed] [Google Scholar]
  25. Schentag J. J., Nix D. E., Adelman M. H. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP. 1991 Oct;25(10):1050–1057. doi: 10.1177/106002809102501003. [DOI] [PubMed] [Google Scholar]
  26. Smith I. L., Schentag J. J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci. 1984 Feb;73(2):281–282. doi: 10.1002/jps.2600730239. [DOI] [PubMed] [Google Scholar]
  27. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]
  28. Stratton C. W. The role of the microbiology laboratory in the treatment of infective endocarditis. J Antimicrob Chemother. 1987 Sep;20 (Suppl A):41–49. doi: 10.1093/jac/20.suppl_a.41. [DOI] [PubMed] [Google Scholar]
  29. Watanakunakorn C. The antibacterial action of vancomycin. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S210–S215. [PubMed] [Google Scholar]
  30. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
  31. Zimmermann A. E., Katona B. G., Plaisance K. I. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy. 1995 Jan-Feb;15(1):85–91. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES